MEN1 and acute myeloid leukemia: Menin interaction inhibitors such as revumenib and ziftomenib have been used in relapsed/refractory settings in NPM1MT- and KMT2A-rearranged AML, with complete or complete remission with a partial hematologic recovery rate (CR/CRh) of around 30% [46,47,48].